Inari Medical (NASDAQ:NARI) Rating Reiterated by Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Inari Medical (NASDAQ:NARI – Free Report) in a research note released on Friday morning, Benzinga reports. Canaccord Genuity Group currently has a $75.00 target price on the stock. NARI has been the topic of several other reports. Piper Sandler downgraded shares of Inari Medical from […]

Leave a Reply

Your email address will not be published.

Previous post Science Applications International’s (SAIC) “Hold” Rating Reiterated at Truist Financial
Next post Stifel Nicolaus Reaffirms “Buy” Rating for Micron Technology (NASDAQ:MU)